N-Acetyl-L-Carnosine functions as a prodrug that penetrates tissues—particularly the cornea—and is subsequently deacetylated to release active L-carnosine, exerting potent antioxidant, anti-glycation, and metal-ion chelation activities. Its most extensively researched application is in 1% ophthalmic formulations (e.g., Can-C), where clinical studies suggest it may help reduce oxidative stress in the lens and potentially slow the progression of age-related cataracts, though major ophthalmological bodies such as the Royal College of Ophthalmologists have noted that existing evidence derives primarily from specific research groups and requires further independent, large-scale validation. Beyond ophthalmic use, it is utilized in topical skincare as an anti-aging agent to inhibit advanced glycation end-products (AGEs) and in laboratory research on cellular senescence and lipid peroxidation. The compound is typically supplied at >98% purity for research and is soluble in water and ethanol; it should be stored desiccated at -20°C, protected from light and moisture. It is important to distinguish N-Acetyl-L-Carnosine from N-Acetylcysteine (NAC), as they are chemically distinct compounds with different mechanisms. While it is approved for ophthalmic use in some countries (e.g., Russia), it is not FDA-approved as a drug for cataract treatment in the United States and is marketed as a dietary supplement ingredient or research compound; oral bioavailability remains poor due to gastrointestinal breakdown, making topical and ophthalmic routes the primary effective delivery methods.